Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 12;23(1):5.
doi: 10.1186/s12955-025-02332-8.

Health utility scores of six common cancers in China measured by SF-6Dv2

Yuchun Tao #  1 , Yiyin Cao #  1 , Lijun Xu  1 , Jiaxuan Shi  1 , Lei Leng  1 , Hongbin Yang  2 , Tiemin Zhai  3 , Weidong Huang  4
Affiliations

Health utility scores of six common cancers in China measured by SF-6Dv2

Yuchun Tao et al. Health Qual Life Outcomes. .

Abstract

Purpose: Given the recent update of SF-6Dv2, detailed data on utility scores for cancer patients by cancer type remain scarce in China and other regions, which limits the precision of cost-utility analyses (CUA) in cancer interventions. The aim of the study was to systematically evaluate utility scores of six common cancers in China measured using SF-6Dv2, and identify the potential factors associated with utility scores.

Methods: A hospital-based cross-sectional survey was conducted from August 2022 to December 2023. It recruited 896 cancer patients from three tertiary hospitals in China, including 270 with lung cancer, 96 with stomach cancer, 88 with liver cancer, 71 with oesophagus cancer, 142 with colorectum cancer, and 160 with breast cancer. The validated Simplified Chinese version of the SF-6Dv2 was used to calculate utilities based on the Chinese value set, and the utility values were described using the mean and standard deviation (SD). Participants' socio-demographic, behavioral and clinical characteristics were also obtained from the survey. Univariate and multivariate linear regression models were performed to explore the impact of these three categories of characteristics on utility scores derived from SF-6Dv2 for the total cancer patients and each cancer group.

Results: The mean utility score was 0.66 (SD = 0.26) for the total cancer sample, 0.66 (SD = 0.25) for lung cancer, 0.75 (SD = 0.23) for stomach cancer, 0.69 (SD = 0.24) for liver cancer, 0.69 (SD = 0.24) for oesophagus cancer, 0.65 (SD = 0.31) for colorectum cancer, and 0.57 (SD = 0.24) for breast cancer. Multivariate linear regression analysis indicated that patients who were older, from larger families, under greater economic pressures, undergoing fewer health examinations, smoking, and in advanced cancer stages had lower utility scores in the total cancer sample (p<0.05), with variations observed across different cancer types.

Conclusions: This study is one of the first to apply the SF-6Dv2 to a heterogeneous group of cancer patients, providing evidence for conducting CUA with SF-6Dv2 across six common cancers in China. In addition, the study provides a basis for improving interventions for different cancer types.

Keywords: Cancer; China; Health utility; SF-6Dv2.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The protocol of this study received approval from the Ethics Committee of Harbin Medical University (HMUIRB2023005). Informed consent was obtained from all individual participants included in the study. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Utility scores of SF-6Dv2 for the total cancer patients and each cancer group
Fig. 2
Fig. 2
Responses to the SF-6Dv2 descriptive system from the total cancer patients and each specific cancer group
Fig. 3
Fig. 3
Mean health utility of study participants according to their cancer stage
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783–91. 10.1097/cm9.0000000000001474. - PMC - PubMed
    1. Sun D, Li H, Cao M, He S, Lei L, Peng J, Chen W. Cancer burden in China: trends, risk factors and prevention. Cancer Biol Med. 2020;17(4):879–95. 10.20892/j.issn.2095-3941.2020.0387. - PMC - PubMed
    1. Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, Xia C, Sun K, Yang Z, Li H, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5):e555–67. 10.1016/s2214-109x(18)30127-x. - PubMed
    1. Zheng RS, Chen R, Han BF, Wang SM, Li L, Sun KX, Zeng HM, Wei WW, He J. [Cancer incidence and mortality in China, 2022]. Zhonghua Zhong Liu Za Zhi. 2024;46(3):221–31. 10.3760/cma.j.cn112152-20240119-00035. - PubMed
    1. Wang Y, Yan Q, Fan C, Mo Y, Wang Y, Li X, Liao Q, Guo C, Li G, Zeng Z, et al. Overview and countermeasures of cancer burden in China. Sci China Life Sci. 2023;66(11):2515–26. 10.1007/s11427-022-2240-6. - PMC - PubMed

LinkOut - more resources